» Articles » PMID: 8762747

The Views of General Practitioners on Community Carrier Screening for Cystic Fibrosis

Overview
Journal Br J Gen Pract
Specialty Public Health
Date 1996 May 1
PMID 8762747
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recent developments in molecular genetics have made it possible to identify carriers of the cystic fibrosis (CF) mutation, regardless of family history, before they have an affected child. Using these techniques, population or 'community' carrier screening can offer informed reproductive choice to individuals and couples who would not otherwise know of their risk of having a CF child.

Aim: This study set out to assess the views of general practitioners (GPs) on community carrier screening for CF and to consider the factors that influence their willingness to offer it themselves.

Method: A self-administered questionnaires was sent to all 616 GPs in four areas of North Thames (West) Region.

Results: Two-thirds of respondents indicated that identifying carrier couples to offer genetic counselling before conception was a very important benefit of community carrier screening. Two-thirds felt that general practice was the most appropriate place in which to offer it, and similar proportions that the most appropriate times to do so were when a close relative was diagnosed and when seeking family planning. About half wanted to offer community carrier screening themselves; this was related to experience with CF patients and CF carrier testing, and estimates of the numbers of CF carriers in the practice.

Conclusions: There is considerable support among GPs for community carrier screening for CF in general practice, particularly in the context of family planning services. Knowledge and experience of CF increase GPs' willingness to offer it themselves.

Citing Articles

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.

Hussein N, Henneman L, Kai J, Qureshi N Cochrane Database Syst Rev. 2021; 10:CD010849.

PMID: 34634131 PMC: 8504980. DOI: 10.1002/14651858.CD010849.pub4.


Expanded universal carrier screening and its implementation within a publicly funded healthcare service.

Rowe C, Wright C J Community Genet. 2019; 11(1):21-38.

PMID: 31828606 PMC: 6962405. DOI: 10.1007/s12687-019-00443-6.


Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.

Hussein N, Weng S, Kai J, Kleijnen J, Qureshi N Cochrane Database Syst Rev. 2018; 3:CD010849.

PMID: 29537064 PMC: 6494256. DOI: 10.1002/14651858.CD010849.pub3.


Exploring approaches to facilitate family communication of genetic risk information after cystic fibrosis population carrier screening.

Gorrie A, Archibald A, Ioannou L, Curnow L, McClaren B J Community Genet. 2017; 9(1):71-80.

PMID: 28971321 PMC: 5752656. DOI: 10.1007/s12687-017-0337-1.


Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.

Hussein N, Weng S, Kai J, Kleijnen J, Qureshi N Cochrane Database Syst Rev. 2015; (8):CD010849.

PMID: 26264938 PMC: 6486309. DOI: 10.1002/14651858.CD010849.pub2.


References
1.
Magnay D, Wilson O, el Hait S, Balhamar M, Burn J . Carrier testing for cystic fibrosis: knowledge and attitudes within a local community. J R Coll Physicians Lond. 1992; 26(1):69-70. PMC: 5375424. View

2.
Watson E, Williamson R, Chapple J . Attitudes to carrier screening for cystic fibrosis: a survey of health care professionals, relatives of sufferers and other members of the public. Br J Gen Pract. 1991; 41(347):237-40. PMC: 1371586. View

3.
Williamson R . Universal community carrier screening for cystic fibrosis?. Nat Genet. 1993; 3(3):195-201. DOI: 10.1038/ng0393-195. View

4.
Burn J . Screening for cystic fibrosis in primary care. BMJ. 1993; 306(6892):1558-9. PMC: 1677992. DOI: 10.1136/bmj.306.6892.1558. View

5.
Harris H, Scotcher D, Hartley N, Wallace A, Craufurd D, Harris R . Cystic fibrosis carrier testing in early pregnancy by general practitioners. BMJ. 1993; 306(6892):1580-3. PMC: 1678000. DOI: 10.1136/bmj.306.6892.1580. View